Confidential Business Information Disclosure UpdatePublished on April 17, 2017
The Health Minister can disclose confidential business information (CBI) to protect or promote health or safety. A draft guidance document on the disclosure of CBI was published on Mar 10, 2016 and Health Canada underwent a consultation period. Comments received by May 24, 2016 have been incorporated into the revised guidance. A summary of comments received is available on request by email to email@example.com. This document is intended for health researchers and professionals, patient groups, and pharma and medical device industries. The document includes information on the following.
- paragraph 21.1(3)(c) of the Food and Drugs Act
- principals and considerations for Health Canada's exercise of the authority under paragraph 21.1(3)(c) of the Food and Drugs Act
- protection of personal information and respecting participant's informed consent
- protection against commercial use
- maintaining confidentiality of disclosed information
- process to review requests for disclosure
- requirements for persons requesting disclosure of confidential business information under paragraph 21.1(3)(c)
- findings generated from disclosed information
- forms and additional information:
- review process flow chart
- tools for finding regulatory information
Completed CBI disclosure requests under s21.1(3)(c) of the Food and Drugs Act can be found here.
Pragmatic Clinical Trials: Testing Treatments in the Real-World
What is a Pragmatic Clinical Trial? Clinical trials can be designed to be either pragmatic or explanatory. Explanatory trials are designed to find out whether a treatment...
The FDA Announces Proposed Rule: Nonprescription Drug Product with an Additional Condition for Nonprescription Use – June 28, 2022
The FDA is announcing the availability of the proposed rule Nonprescription Drug Product with an Additional Condition for Nonprescription Use (Docket No. FDA-2021-N-0862)....